On September 5, 2025, BioNTech SE reported that its Phase 3 trial with Duality Biologics met its primary endpoint for treating HER2-positive breast cancer, signaling a positive advancement in their research.
AI Assistant
BIONTECH SE
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.